



Can-Fite BioPharma Announces the Completion of Patient Enrollment for the Phase 2b Rheumatoid Arthritis Study

Petach Tikva, Israel, August 12, 2013: Can-Fite BioPharma (TASE: CFBI, OTC: CANFY), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has completed patient enrollment for a phase 2b clinical study of CF101 for the treatment of patients with Rheumatoid Arthritis.

The patients were randomized into two groups treated with 1 mg of CF101 as a stand-alone drug and placebo for a period of 12 weeks. The primary end point of this study is ACR20 and among the secondary end points are ACR50 and ACR70. Patients were enrolled to the study based on a blood test analysis of a biomarker, the A3 adenosine receptor, the CF101 target. Only patients with over-expression of the target have been recruited to the study. The results of this study are expected to be announced in the fourth quarter this year.

Can-Fite CEO Pnina Fishman, Ph.D., commented "We are very pleased with the completion of patient enrollment to the RA study and are looking forward to release the results of this study during the fourth quarter this year".

About Can-Fite Biopharma Ltd.

Can-Fite Biopharma Ltd is an Israeli public company, the ordinary shares of which are traded on the Tel Aviv Stock Exchange (TASE: CFBI). American Depositary Receipts of the company are traded on the over-the-counter market (OTC: CANFY). The company, which commenced business activity in 2000, was founded by Pnina Fishman, Ph.D., researcher in the Rabin Medical Center, and Ilan Cohn Ph.D., patent attorney and senior partner at Reinhold Cohn Patent Attorneys. Pnina Fishman serves as CEO of the company. The company was founded on the basis of Fishman's scientific findings, and is focused on the development of small molecule orally bioavailable drugs, ligands to the A3 adenosine receptor. The latter mediates anti-inflammatory and anti-cancer effects and is suggested as a biological predictive marker. The company's lead drug, CF101, is in clinical development for the treatment of autoimmune inflammatory diseases. The CF102 drug candidate is being developed for the treatment of liver diseases. Can-Fite has a wealth of clinical experience: to date, more than 700 patients have participated in clinical trials conducted by the company. Can-Fite previously licensed its activity in the ophthalmic field to OphthaliX Inc., in which it holds a controlling interest (OTC: OPLI).

Contact:

KCSA Strategic Communications
Jeff Corbin / Phil Carlson
jcorbin@kcsa.com / pcarlson@kcsa.com
212-896-1233



Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Can-Fite's business can be found in its periodic filings with the Tel Aviv Stock Exchange.